The FDA has approved a new once-daily HIV pill from Gilead called Bixlenvo, designed to simplify treatment for adults with suppressed HIV who face challenges with current regimens. This single-tablet combines bictegravir, a key component of Gilead’s blockbuster Biktarvy, with lenacapavir, a novel capsid inhibitor central to Gilead’s long-term HIV strategy. Bixlenvo is aimed at patients who either cannot use existing one-pill options due to drug resistance or side effects, or those wanting to switch to a new treatment option while maintaining viral suppression.

Gilead estimates that over 5% of Americans living with HIV fall into the group who could benefit from Bixlenvo, which offers a simpler alternative to complex regimens involving multiple pills. The monthly list price is $4,595, comparable to other daily single-tablet HIV therapies, although assistance programs are available for uninsured or underinsured patients. Dr. Jared Baeten, Gilead’s clinical development head, emphasized that the new pill addresses unmet needs by consolidating therapy for individuals on complicated treatments while also expanding choices for those stable on single-pill regimens.

Clinical approval was supported by two Phase 3 trials involving patients with long treatment histories and multidrug resistance, some of whom were taking up to 11 tablets daily before switching. These studies showed Bixlenvo maintained viral suppression at rates similar to previous therapies and was well tolerated with manageable side effects such as headache and nausea. Participants like Timothy Cameron, diagnosed in the 1980s and dealing with resistant virus strains, reported that the new once-daily pill significantly simplified their treatment routine without compromising effectiveness.

Bixlenvo is part of Gilead’s broader effort to diversify HIV treatment options centered around lenacapavir, including daily, weekly, and long-acting injectable forms. This portfolio aims to give patients more flexibility to choose regimens that best fit their lifestyles and improve long-term adherence and outcomes. According to Baeten, the new pill does not replace Biktarvy but adds an important option for individualized HIV care, especially for people aging with HIV who may face additional health challenges linked to both the virus and treatment complexity.